Related Experiment Video

Updated: Jun 27, 2026

Protocol for Relative Hydrodynamic Assessment of Tri-leaflet Polymer Valves
11:12

Protocol for Relative Hydrodynamic Assessment of Tri-leaflet Polymer Valves

Published on: October 17, 2013

[Valvular bioprostheses and anticoagulation]

Isabelle Chatton Chambaz1, Mathieu Nendaz

  • 1Service de médecine interne générale, HUG, 1211 Genève 14. isabelle.chatton@hcuge.ch

Revue Medicale Suisse
|November 26, 2008
PubMed

Insights

Cardiac valve replacement carries a thromboembolic risk. Current anticoagulation guidelines for biological valves are inconsistent, prompting research into whether anticoagulation is always necessary, especially for aortic valve prostheses.

Area of Science:

  • Cardiology
  • Cardiac Surgery
  • Biomaterials Science

Context:

  • Cardiac valve replacement, particularly with bioprostheses, presents a significant thromboembolic risk.
  • Existing anticoagulation recommendations for biological heart valves lack uniformity and consistent clinical application.
  • Some institutions maintain prolonged anticoagulation for all valve replacement patients, increasing bleeding risks.

Purpose:

  • To evaluate the necessity of current anticoagulation protocols for biological heart valves.
  • To investigate the potential for reduced anticoagulation in specific patient subgroups, such as those receiving aortic valve prostheses without additional embolic risk factors.

Summary:

  • Cardiac valve replacement with bioprostheses is linked to thromboembolic events, especially post-surgery.
  • Current anticoagulation practices for biological valves are variable, with some centers over-anticoagulating patients, leading to bleeding complications.
  • Emerging evidence suggests anticoagulation may not be required for biological aortic valves in patients without other embolic risk factors.

Impact:

  • Informing the development of more precise and individualized anticoagulation strategies post-cardiac valve replacement.
  • Potentially reducing bleeding complications associated with unnecessary anticoagulation.
  • Highlighting the need for further prospective, randomized trials to solidify evidence for optimized bioprosthesis management and thromboembolism prevention.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...